SF500
SF500 is a biotechnology acceleration program and impact investment firm based in Rosario, Argentina, established in 2022. The company focuses on transforming scientific projects into successful biotech startups by identifying outstanding scientific ideas and assembling strong teams with both scientific and business expertise. SF500 runs a rigorous 12-week program twice a year for 15 selected candidates, emphasizing science, team dynamics, and product development. Participants in the program may receive a pre-seed investment of $250,000. The firm offers extensive support through its dedicated portfolio management team, which assists startups from the investment phase onward, providing services such as legal assistance, intellectual property support, lab facilities, and connections to a network of international investors. SF500 aims to invest in areas such as carbon neutrality, biomaterials, regenerative agriculture, functional foods, diagnostics, health, and wellness.
PILL.AR is a biotechnology company focused on developing personalized medication solutions aimed at enhancing individuals' quality of life. By leveraging innovative pharmaceutical technology, PILL.AR tailors treatments to meet the unique needs of each patient. Currently, the company operates in Stealth Mode, indicating a phase of discreet development and potential future offerings in the personalized medicine sector.
NotFossil is a biotechnology company that offers hydrocarbon bioremediation services for wastewater treatment.
Gameet is a biotechnology startup that emulates the natural processes of sperm selection and growth in a device printed with 3D technology.
Tintte is a company focused on transforming the textile dyeing industry through innovative biotechnology. By utilizing specially selected bacteria, Tintte develops bio dyes and bio compounds that eliminate the need for harmful chemicals and toxins, significantly reducing water and energy consumption. Their biotechnological process allows for the sustainable production, deposition, and fixation of pigments on textiles, offering an efficient solution that can be scaled to meet industry demands. This approach not only enhances the sustainability of textile dyeing but also aims to drastically reduce pollution associated with traditional methods.
MesencHyal-T is a biotechnology company that develops cellular medical therapies for the treatment of tissue regeneration.
BioMetallum is a biomining company that designs and develops solutions for extracting lithium and other metals.
Inmet S.A. is a biotechnology company that focuses on optimizing microorganisms for the bio-transformation of agro-industrial residues into high-value compounds. The company is dedicated to developing environmentally friendly technologies that convert waste into valuable products, allowing clients to replace chemical products with sustainable and biodegradable biological materials. By employing a multidisciplinary approach in synthetic biology, Inmet designs and genetically optimizes microorganisms for various industrial applications, ensuring minimal environmental impact while utilizing low-cost raw materials. Through its innovative solutions, Inmet aims to generate technologies that are safe for humans and beneficial for the environment.
Trebe Biotech is a biotechnology startup focused on the production of complex recombinant proteins through an innovative high-throughput platform. The company specializes in offering customized services tailored for the veterinary and diagnostic medicine sectors. By providing a flexible production platform, Trebe Biotech enables its strategic partners to obtain high-quality proteins that meet their specific needs, thereby supporting advancements in these critical areas of medicine.
Mycorium Biotech is focused on upcycling waste to produce bioleather, a sustainable alternative to synthetic leather. By utilizing a fungal biotech platform, the company transforms discarded materials into a biodegradable, mycelium-based product aimed at addressing the environmental challenges faced by the fashion industry, which is known for its significant pollution levels. Mycorium Biotech promotes responsible production and consumption practices in line with sustainability goals, providing eco-friendly materials that allow consumers to choose garments made from organic bioleather.
Exomas develops disruptive solutions based on exosomes derived from neural stem cells for the preventive or regenerative treatment of nervous tissue affected by neurodegenerative diseases. These exosomes have the ability to induce the proliferation of neural stem cells and their differentiation into functional neurons, thus exerting a neuroregenerative effect on the affected tissue.
Unibaio specializes in biodegradable nano-encapsulation technology aimed at optimizing agrochemical delivery while minimizing environmental impact. The company develops innovative materials that create micro-nanocapsules, which enhance the efficacy of fertilizers and pesticides by improving their uptake and reducing harmful chemical runoff. Unibaio's solutions enable pesticide manufacturers to adjust their formulations to comply with stringent environmental regulations without altering the active ingredients used by farmers. By using natural compounds such as shrimp waste and clay, Unibaio promotes a circular economy, contributing to lower application costs for farmers and improved agricultural yields. Their technology is applicable across various pesticide and fertilizer types, including traditional chemicals and organic options, ultimately supporting the agricultural sector in reducing toxicity and enhancing the health of crops.
MultiplAI Health specializes in developing advanced blood screening tests aimed at detecting complex diseases, including cardiovascular disorders and cancers. Utilizing RNA sequencing and artificial intelligence, the company analyzes numerous biomarkers in blood samples to facilitate early diagnosis. Their innovative approach allows for universal remote screening, making it possible to conduct tests using simple blood samples that can be administered anywhere, at a significantly lower cost compared to traditional diagnostic methods. This technology not only supports preventative screening for asymptomatic individuals but also aids in post-treatment monitoring, enabling clinicians to make more accurate prognoses and treatment decisions based on enhanced diagnostic stratification.
TELL is on a mission to revolutionize the fight against neurodegenerative diseases like Alzheimer's, Parkinson's, and frontotemporal dementia. The company's innovative approach to brain health combines automated speech and language analysis with cutting-edge AI technology to detect early markers and provide reliable data to get to diagnoses. The company's HIPAA-compliant SaaS solution is designed to address the challenges of early detection, specificity, cost, access, and reliability. By offering a unified, user-friendly, and scalable tool for discovering and implementing novel markers, we're bringing hope to patients, caregivers, and healthcare professionals across the globe. So, whether you're a patient, physician, biotech company, health insurance provider, or government agency, TELL is here to help you make better decisions and improve brain health for all.
Eirú is a biotechnology company that offers a biodiversity MRV system for conservation related decision making.
At M4Life, we have developed the first solution based on bio-trained microbes to recover unproductive lands and halt deforestation. With our unique approach, we introduce bio-trained microbes into the soil through seeds, benefiting the plants and restoring degraded soils. We enable plants to adapt and thrive under abiotic stress, such as drought, salinity, or high temperatures, increasing crop yields by 44%, improving nutritional content, and capturing tons of CO2.
Eureka Nanobioengineering specializes in the development of innovative nanobiodevices and advanced functional nanobiomaterials through its proprietary platform. This platform facilitates protein engineering to manipulate self-assembly mechanisms of various viral proteins, enabling applications in areas such as immune system programming, allergen immunotherapy, and vaccine development. The company's technology also supports antibody and small molecule conjugation, personalized medicine, and therapeutics, providing clients with versatile solutions across multiple scientific and technological domains. By focusing on cost-effective next-generation products, Eureka Nanobioengineering aims to advance the field of nanobiotechnology and improve healthcare outcomes.
Limay Biosciences specializes in the development of innovative molecular testing solutions aimed at enhancing food quality and health decision-making. The company creates simple, precise, and cost-effective tools that facilitate on-site testing of various DNA, RNA, and protein targets. By leveraging advanced biotechnologies, Limay Biosciences provides businesses with automated and accessible testing services, allowing for real-time analysis and improved decision-making in diverse applications.
BiotaLife Skin is a biotechnology company that offerssSkin microbiome detection and treatment services.
Oncoliq is a startup focused on developing innovative screening methods for early cancer detection through liquid biopsy, utilizing small blood samples. The company is primarily targeting the early detection of breast and prostate cancer, while also exploring the possibility of identifying other cancer types. By leveraging the detection of microRNAs, Oncoliq aims to create a simple blood test capable of detecting up to 50 different types of cancer. This approach is designed to enable effective early detection, potentially improving patient outcomes through timely diagnosis.
BEAM CropTech is a biotechnology company that develop genetic engineering technologies for optimizing growth and increasing crop yield.
Dharma Bioscience is at the forefront of developing an innovative injectable treatment utilizing modified microRNAs to promote cartilage regeneration in patients with osteoarthritis. This advanced therapy offers a straightforward administration method for physicians worldwide, reducing the necessity for invasive joint replacement surgeries. By providing a non-invasive alternative, this injectable solution not only minimizes recovery time and associated costs but also presents patients with a safer and more accessible option for managing their condition.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.